| 1. | | Recruiting | Environmental Contaminants and Infant Development
Conditions: Mercury Poisoning; Lead Poisoning |
| 2. | | Recruiting | Effect of environmental exposures on the egg fertilizing ability of human sperm
Conditions: Male Infertility; Testicular Diseases; Urologic and Male Genital Diseases; Lead Poisoning |
| 3. | | Recruiting | Pesticide Exposure Pathways for Farmworker Children
Condition: Poisoning |
| 4. | | Recruiting | A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency
Conditions: Glucosephosphate Dehydrogenase Deficiency; Favism |
| 5. | | Recruiting | Study of Human Botulism Immunoglobulin in Infants With Botulism
Conditions: Infant Botulism; Botulism |
| 6. | | Recruiting | Botulinum Toxin for the Treatment of Involuntary Movement Disorders
Conditions: Chorea; Drug Induced Dyskinesia; Movement Disorder; Muscular Disease; Tic Disorder |
| 7. | | Recruiting | Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
Conditions: Drug Toxicity; radiation toxicity; limited stage small cell lung cancer |
| 8. | | Recruiting | Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer
Conditions: stage II bladder cancer; stage III bladder cancer; stage IV bladder cancer; Drug Toxicity |
| 9. | | Recruiting | Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer
Conditions: adenocarcinoma of the pancreas; Drug Toxicity; Pancreatic Cancer |
| 10. | | Recruiting | Brain Function in Children Previously Treated on Clinical Trials POG-9605 and POG-9201
Conditions: neurotoxicity; long-term effects secondary to cancer therapy in children |
| 11. | | Recruiting | Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors
Conditions: cardiac toxicity; unspecified childhood solid tumor, protocol specific |
| 12. | | Recruiting | EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer
Conditions: neurotoxicity; stage I breast cancer; stage II breast cancer; stage IIIA breast cancer; stage IIIB breast cancer; stage IIIC breast cancer |
| 13. | | Recruiting | Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
Conditions: Drug Toxicity; primary systemic amyloidosis |
| 14. | | Recruiting | Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy
Conditions: Drug Toxicity; childhood acute lymphoblastic leukemia |
| 15. | | Recruiting | Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
Conditions: acute leukemia; childhood large cell lymphoma; childhood small noncleaved cell lymphoma; Drug Toxicity |
| 16. | | Recruiting | Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Gynecologic Malignancy
Conditions: Endocrine Cancer; female reproductive cancer; neurotoxicity |
| 17. | | Recruiting | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck
Conditions: Drug Toxicity; female reproductive cancer; Head and Neck Cancer; thorax and respiratory cancer |
| 18. | | Recruiting | Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Conditions: Quality of Life; neurotoxicity; Pain; unspecified adult solid tumor, protocol specific |
| 19. | | Recruiting | Dextroamphetamine-Amphetamine Compared With Methylphenidate in Treating Children With Depression and Problems With Memory, Attention, and Thinking Caused By Cancer Treatment
Conditions: unspecified childhood solid tumor, protocol specific; Depression; neurotoxicity |
| 20. | | Recruiting | Rituximab, Carboplatin, Cyclophosphamide, and Etoposide or Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Sodium Thiosulfate and Cytarabine in Treating Patients With Refractory or Recurrent Primary CNS Lymphoma
Conditions: Drug Toxicity; Thrombocytopenia; intraocular lymphoma; primary central nervous system lymphoma |
| 21. | | Recruiting | Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
Conditions: Anal Cancer; Drug Toxicity; radiation enteritis; Rectal Cancer |
| 22. | | Recruiting | Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Conditions: Anemia; Drug Toxicity; Neutropenia; Non-small cell lung cancer |
| 23. | | Recruiting | Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
Conditions: adult solid tumor; Breast Cancer; Lung Cancer; neurotoxicity; ovarian epithelial cancer; Prostate Cancer |
| 24. | | Recruiting | Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal Therapy for Acute Lymphoblastic Leukemia
Conditions: long-term effects secondary to cancer therapy in children; neurotoxicity; psychosocial effects/treatment; ... |
| 25. | | Not yet recruiting | Melphalan and Amifostine Followed By Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Conditions: Drug Toxicity; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 26. | | Recruiting | Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer
Conditions: Drug Toxicity; hormonal changes; stage I breast cancer; stage II breast cancer |
| 27. | | Recruiting | Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
Conditions: Diarrhea; Drug Toxicity; disseminated neuroblastoma; recurrent neuroblastoma |
| 28. | | Recruiting | Radiation Therapy, Carboplatin, and Paclitaxel With or Without Amifostine in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer
Conditions: Drug Toxicity; Head and Neck Cancer; oral complications of chemotherapy and head and neck radiation; radiation toxicity |
| 29. | | Recruiting | Reducing Pesticide Exposure in Minority Families
Condition: Disorders of Environmental Origin |
